NEWAMSTERDAM PHARMA CO NV

NewAmsterdam Pharma insider buys 125,000 shares, boosting CSO stake and hinting at upcoming clinical milestones that could lift the stock.

Inside NewAmsterdam Pharma’s July 20 insider trades reveal a strategic buy‑low, sell‑high pattern that signals confidence, liquidity needs, and future growth in the cardiovascular space.

Insider trading by Newamsterdam Pharma’s director shows a hedging strategy that preserves capital while signaling confidence in the firm’s long‑term prospects.

CEO buys shares in Newamsterdam Pharma amid Phase‑III CLL study; insider buying signals confidence while investors watch upcoming trial data and FDA review.

Newamsterdam Pharma insider buying signals future upside as NAM‑01 phase‑2 trials show 1.3% HbA1c drop and a potential 160% gain if Phase‑3 succeeds.

Newamsterdam insider Kooij Louise Frederika buys 38,172 shares at $10.90, 5.1% stake rise, hinting confidence amid sales‑buy cycle strategy.

Newamsterdam Pharma CFO’s Rule‑10b5‑1 buy signals confidence in early‑stage heart‑failure drug; investors should watch Phase III milestones and regulatory filings for true value.